Abstract
This themed section of the British Journal of Pharmacology stems from the ninth in the series of MPGPCR meetings, held as a joint initiative with the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists in Melbourne, Australia, from 28 to 30 November 2016. The articles provide insights into how GPCR environment can influence function, the identification of new drug targets based on allostery, biased agonism and oligomerization and the importance of taking into account sexual dimorphism in developing animal models for the evaluation of potential treatments for cardiovascular disease. In addition, novel approaches are presented for the treatment of metabolic disease, disturbances of calcium homeostasis and migraine.
| Original language | English |
|---|---|
| Pages (from-to) | 4005-4008 |
| Number of pages | 4 |
| Journal | British Journal of Pharmacology |
| Volume | 175 |
| Issue number | 21 |
| DOIs | |
| Publication status | Published - 1 Nov 2018 |
Cite this
}
Molecular pharmacology of GPCRs. / Langmead, Christopher J.; Summers, Roger J.
In: British Journal of Pharmacology, Vol. 175, No. 21, 01.11.2018, p. 4005-4008.Research output: Contribution to journal › Editorial › Other
TY - JOUR
T1 - Molecular pharmacology of GPCRs
AU - Langmead, Christopher J.
AU - Summers, Roger J.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - This themed section of the British Journal of Pharmacology stems from the ninth in the series of MPGPCR meetings, held as a joint initiative with the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists in Melbourne, Australia, from 28 to 30 November 2016. The articles provide insights into how GPCR environment can influence function, the identification of new drug targets based on allostery, biased agonism and oligomerization and the importance of taking into account sexual dimorphism in developing animal models for the evaluation of potential treatments for cardiovascular disease. In addition, novel approaches are presented for the treatment of metabolic disease, disturbances of calcium homeostasis and migraine.
AB - This themed section of the British Journal of Pharmacology stems from the ninth in the series of MPGPCR meetings, held as a joint initiative with the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists in Melbourne, Australia, from 28 to 30 November 2016. The articles provide insights into how GPCR environment can influence function, the identification of new drug targets based on allostery, biased agonism and oligomerization and the importance of taking into account sexual dimorphism in developing animal models for the evaluation of potential treatments for cardiovascular disease. In addition, novel approaches are presented for the treatment of metabolic disease, disturbances of calcium homeostasis and migraine.
UR - http://www.scopus.com/inward/record.url?scp=85054775391&partnerID=8YFLogxK
U2 - 10.1111/bph.14474
DO - 10.1111/bph.14474
M3 - Editorial
VL - 175
SP - 4005
EP - 4008
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
SN - 1476-5381
IS - 21
ER -